Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X:
“PANKU-Esophagus01 phase 3 (JAMA):
EGFRxHER3 bsADC iza-bren vs chemo, 2L ESCC (n=497)
- mPFS 4.17 vs 1.97 mo, HR 0.50
- mOS 9.79 vs 7.20 mo, HR 0.63 (interim)
- G≥3 TRAEs 85.1 vs 59.3%
China-only, 80 sites.”

PANKU-Esophagus01 main findings:
- Progression-free survival (PFS) was significantly longer with iza-bren than with chemotherapy. Median PFS, assessed by blinded independent central review, was 4.2 months versus 2.0 months, respectively (HR, 0.50; P < 0.0001), representing a 50% reduction in the risk of disease progression or death.
- Iza-bren demonstrated a higher objective response rate (ORR) than chemotherapy, with responses observed in 35.3% of patients compared with 13.1%, respectively. The findings indicate substantially greater antitumor activity in patients whose disease progressed after first-line PD-1/PD-L1 inhibitor and platinum-based chemotherapy.
- Grade 3 or higher treatment-related adverse events (TRAEs) were more frequent with iza-bren than chemotherapy (85.1% vs 60.2%), predominantly due to hematologic toxicities. However, treatment discontinuation rates due to TRAEs were relatively low (2.0% vs 3.3%), and the overall safety profile was considered manageable.
Ttile: Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Authors: Zhihao Lu, Zhangzhou Huang, Xiangjiao Meng, Yun Fan, Tao Wu, Qingsong Pang, Feng Wang, Yanqiao Zhang, Shegan Gao, Tianshu Liu, Jin Zhou, Yong Fang, Ning Li, Wei Li, Guochun Cao, Shoubing Zhou, Na Li, Feng Ye, Yinghua Ji, Jingdong Zhang, Xuwei Cai, Jianping Xiong, Mingjun Zhang, Lixin Wan, Yanhong Gu, Hui Luo, Xiaotian Zhang, Jinglei Qu, Wenhui Yang, Jianzhong Cao, Xueqiang Zhu, Jiayan Chen, Tienan Yi, Yongli Gao, Jiangqiong Huang, Zhenhua Liu, Jun Wang, Fang Ma, Yan Luo, Xuelei Ma, Jianfei Fu, Shubo Ding, Yu Liu, Sa Xiao, Hai Zhu, Yi Zhu, Lin Shen
Read the full article:
You may also be interested in:
Aakash Desai: Predictors of Early Progression With First-Line Osimertinib in EGFR-Mutant NSCLC
Erika Hamilton Shares PANKU-Breast01 Phase III Results in Metastatic Breast Cancer
Sherene Loi: Izalontamab Brengitecan Improves PFS in HR+/HER2− Breast Cancer in China